Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma

Autor(es)

Uno, Miyuki ^[1] ; Oba-Shinjo, Sueli Mieko ^[1] ; Camargo, Anamaria Aranha ^[2] ; Moura, Ricardo Pereira ^[2] ; de Aguiar, Paulo Henrique ^[1] ; Cabrera, Hector Navarro ^[1] ; Begnami, Marcos ^[3] ; Rosemberg, Sergio ^[4] ; Teixeira, Manoel Jacobsen ^[1] ; Nagahashi Marie, Suely Kazue ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med, Dept Neurol, Sao Paulo - Brazil

^[2] Hosp Alemao Oswaldo Cruz, Ludwig Inst Canc Res, Sao Paulo - Brazil

^[3] Diagnostika Patol Cirurgica & Citol, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Fac Med, Dept Pathol, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Clinics; v. 66, n. 10, p. 1747-1755, 2011.
• Citações Web of Science: 42

Resumo

OBJECTIVES: 1) To correlate the methylation status of the O6-methylguanine-DNA-methyltransferase (MGMT) promoter to its gene and protein expression levels in glioblastoma and 2) to determine the most reliable method for using MGMT to predict the response to adjuvant therapy in patients with glioblastoma. BACKGROUND: The MGMT gene is epigenetically silenced by promoter hypermethylation in gliomas, and this modification has emerged as a relevant predictor of therapeutic response. METHODS: Fifty-one cases of glioblastoma were analyzed for MGMT promoter methylation by methylation-specific PCR and pyrosequencing, gene expression by real time polymerase chain reaction, and protein expression by immunohistochemistry. RESULTS: MGMT promoter methylation was found in 43.1% of glioblastoma by methylation-specific PCR and 38.8% by pyrosequencing. A low level of MGMT gene expression was correlated with positive MGMT promoter methylation (p = 0.001). However, no correlation was found between promoter methylation and MGMT protein expression (p = 0.297). The mean survival time of glioblastoma patients submitted to adjuvant therapy was significantly higher among patients with MGMT promoter methylation (log rank = 0.025 by methylation-specific PCR and 0.004 by pyrosequencing), and methylation was an independent predictive factor that was associated with improved prognosis by multivariate analysis. DISCUSSION AND CONCLUSION: MGMT promoter methylation status was a more reliable predictor of susceptibility to adjuvant therapy and prognosis of glioblastoma than were MGMT protein or gene expression levels. Methylation-specific polymerase chain reaction and pyrosequencing methods were both sensitive methods for determining MGMT promoter methylation status using DNA extracted from frozen tissue. (AU)

• Processo FAPESP: 04/12133-6 - Procura de marcadores moleculares relacionados ao diagnóstico e prognóstico de tumores do sistema nervoso central
• Beneficiário: Suely Kazue Nagahashi Marie
• Modalidade de apoio: Auxílio à Pesquisa - Temático